Boston Scientific Corp. (BSX) Shares Bought by Emerald Acquisition Ltd.

Following the transaction, the executive vice president now directly owns 164,681 shares in the company, valued at $4,647,297.82. The total amount of shares outstanding is 1.37 billion, giving the company a market capitalization of about 38.36 billion. The correct version of this report can be viewed at It has outperformed by 80.12% the S&P500.

CAPITAL WORLD INVESTORS lowered its stake in Boston Scientific Corporation (NYSE:BSX) by 0.89% during the September 2017 quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The insider, THEPAUT ERIC FRANCIS YVES, now holds 116,562 shares of BSX. Sector Gamma As reported 1.47 million shares or 6.53% of all its holdings. The company's quarterly revenue was up 5.6% compared to the same quarter a year ago. The stock increased 0.58% or $0.79 during the last trading session, reaching $137.82. About 8.75M shares traded.

The average Wall Street analyst rating for Boston Scientific Corporation is Strong Buy, according to the average of 22 analyst scores. It has outperformed by 2.42% the S&P500. With 163,900 avg volume, 4 days are for Astec Industries Incorporated (NASDAQ:ASTE)'s short sellers to cover ASTE's short positions. (NYSE:TREX) or 285,875 shares.

Investors sentiment decreased to 0.69 in 2017 Q3.

The most recent open market insider trade was Disposition (Non Open Market) of 1,101 shares on a day where the closing price was 24.79. Finally, American Century Companies Inc. boosted its holdings in Boston Scientific by 28.9% during the third quarter. Balyasny Asset Mngmt Limited Liability accumulated 981,924 shares or 0.11% of the stock. 308,705 were reported by Brown Advisory Inc.

In other Boston Scientific news, EVP Michael P. Phalen sold 15,835 shares of the business's stock in a transaction on Saturday, December 29th. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Oppenheimer & Company invested 0.86% of its portfolio in General Electric Company (NYSE:GE). Kennedy Cap Management owns 312,400 shares. Great West Life Assurance Can stated it has 991,691 shares or 0.07% of all its holdings. (NYSE:C) or 20,271 shares. Arizona State Retirement stated it has 15,300 shares. It also reduced Sarepta Therapeutics Inc (Call) (NASDAQ:SRPT) stake by 1.80M shares and now owns 235,000 shares. The institutional investor owned 151,150 shares of the medical equipment provider's stock after acquiring an additional 17,500 shares during the quarter. Exchange Capital invested in 472 shares. Cap One Natl Association reported 104,510 shares. Needham & Company LLC reaffirmed a buy rating and issued a $32.00 price target on shares of Boston Scientific in a research note on Tuesday, October 3rd.

Susquehanna International Group Llp increased Alps Etf Tr (Put) (AMLP) stake by 175,400 shares to 278,800 valued at $3.13M in 2017Q3. Among active positions in the latest quarter, 237 holders increased their positions by a total of 50.69 million shares, 247 holders decreased the positions by a total of 44.34 million shares, and 103 holders held their positions. Voya Inv Ltd Liability Corp owns 0.63% invested in Boston Scientific Corporation (NYSE:BSX) for 10.03M shares. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of $0.31. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. Therefore 27% are positive. Citigroup Inc. had 108 analyst reports since July 21, 2015 according to SRatingsIntel. The firm owned 30,923,730 shares of the company's stock after buying an additional 310,828 shares during the period. The firm has "Buy" rating given on Wednesday, June 28 by Credit Suisse. The stock has "Hold" rating by Oppenheimer on Monday, May 1. On Wednesday, August 2 the insider Sorenson John Bradley sold $208,328. The firm has "Buy" rating by Vertical Group given on Tuesday, September 5. The rating was maintained by RBC Capital Markets with "Buy" on Sunday, November 5. The stock has "Buy" rating by Cowen & Co on Tuesday, July 18. The rating was downgraded by Standpoint Research on Tuesday, January 10 to "Hold". The firm has "Buy" rating given on Tuesday, July 25 by Piper Jaffray. The rating was maintained by Deutsche Bank on Wednesday, August 12 with "Hold".

India vs Australia U-19 World Cup
Gerald Coetzee finished the South African innings with a flourish and his 36 off 14 balls included two fours and three sixes. The Indian captain was, however, dismissed off the very next ball when he was caught by Baxter Holt on the off-side.

Investors sentiment increased to 1.04 in 2017 Q3.

Since October 3, 2017, it had 0 insider purchases, and 1 sale for $575,000 activity. It is positive, as 33 investors sold BSX shares while 166 reduced holdings. 118 funds opened positions while 525 raised stakes. 5 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. 585,338 are held by Aureus Asset Mgmt Limited Liability Company. Primecap Ca has invested 1.02% in Boston Scientific Corporation (NYSE:BSX). Ameritas Ptnrs holds 31,365 shares or 0.04% of its portfolio. Ngam Advsr Limited Partnership reported 46,955 shares stake. Balyasny Asset Mngmt Llc owns 981,924 shares for 0.11% of their portfolio. Caisse De Depot Et Placement Du Quebec holds 0% or 22,126 shares.

Shares of Boston Scientific (NYSE BSX) traded up $0.03 during trading on Friday, reaching $27.46. 43,996 were reported by Creative Planning.

Boston Scientific Corporation (BSX) now trades with a market capitalization of $38.36 Billion. Churchill Management has 139,118 shares for 0.1% of their portfolio.

Since August 1, 2017, it had 0 insider buys, and 11 selling transactions for $14.78 million activity. Also, EVP Timothy A. Pratt sold 10,000 shares of the business's stock in a transaction on Wednesday, November 1st.

Boston Scientific Corporation (BSX) reported its last quarterly earnings on 9/29/2017 where the firm reported its Actual EPS of $0.31/share against the analyst consensus estimate of $0.31/share. 7,397 shares were sold by HANDLEY THOMAS W, worth $966,233.

Related Articles